

Mar 2020-1

CURRENT AND NEAR-TERM PIPELINE

Product	Dosage form	Indication	Dossier availability
CENTRAL NERVOUS SYSTEM			
Amitriptyline	XR tablets 75 mg Film-coated tablets 10, 25, 50, 75 and 100 mg	Major depressive disorders and anxiety	√ Q1 2020
Aripiprazole	Tablets 5, 10, 15, 20 and 30 mg	Schizophrenia, bipolar disorder	√
Baclofen	Injection 10 mg/5ml and 10 mg/20ml	Spasticity	Q4 2020
Clonazepam	Oral drops, solution 2.5 mg/ml Tablets 0.5 and 2 mg	Epilepsy	√ Q1 2020
Duloxetine*	Gastro resistant hard capsules 30, 60, 90 and 120 mg	Major depression, neuropathic pain, anxiety	√
Eslicarbazepine acetate	Film-coated tablets 800 mg	Epilepsy	√
Ethosuximide	Oral solution 50 mg/ml Soft capsules 250 mg	Epilepsy, absence seizures	√
Fampridine	XR tablets 10 mg	Multiple sclerosis	Q1 2020
Fingolimod	Capsules 0.5 mg	Multiple sclerosis	√
Lacosamide	Oral solution 10 mg/ml	Epilepsy	Q1 2020
Levetiracetam	Film-coated tablets 250, 500, 750 and 1000 mg Granules for oral solution 250, 500, 750, 1000, and 1500 mg Oral solution 100 mg/ml	Epilepsy	√
Levomethadone **	Oral solution 5 mg/ml Oral drops, solution 5 mg/ml	Pain, opioid maintenance therapy	√
Memantine hydrochloride	Film-coated tablets 5, 10, 15 and 20 mg Oral solution 10mg/ml	Alzheimer's disease	√
Methocarbamol	Film-coated tablets 500, 750 and 1500 mg	Muscle spasms, pain	√
Olanzapine	Film-coated tablets 2.5, 5, 7.5, 10, 15 and 20 mg Orodispersible tablets 5, 10, 15 and 20 mg	Psychosis, schizophrenia	√
Pramipexol	Tablets 0.088, 0.18, 0.35, 0.7 and 1.1 mg	Parkinson	√
Pregabalin*	Tablets 25, 50, 75, 100, 150, 200, 225 & 300 mg	Neuropathic pain	√
Quetiapine*	Film-coated tablets 25, 50, 100, 150, 200, 300 and 400 mg Orodispersible tablets 25 and 50 mg	Psychosis, schizophrenia, bipolar disorder	√ Q3 2020
Rasagiline	Tablets 1 mg	Parkinson	√
Risperidone	Film-coated tablets 0.5, 1, 2, 3, 4 and 6 mg	Psychosis, schizophrenia, bipolar disorder	√
Rotigotine	Patches 1, 2, 3, 4, 6 and 8 mg/24h	Parkinson	Q1 2021
Sodium Oxybate	Oral Solution 500 mg/ml	Narcolepsy	√
Sulfiamide *	Film-coated tablets 50, 100 and 200 mg	Epilepsy, convulsions	√
Tolcapone	Film-coated tablets 100 mg	Parkinson	√
Tranlycypromine	Film-coated tablets 10, 20 and 40 mg	Depression	Q3 2020
Trazodone	XR tablets 75 and 150 mg	Depression	√
Valproate	Oral solution 60 mg/mL and 300 mg/ml	Epilepsy	√
Zolpidem	Film-toated tablets 10 mg	Insomnia	√
Zonisamide	Hard capsules 25, 50 and 100 mg	Epilepsy	√

* Differentiated product

** Opioid

Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorisation. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorisation. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.

Product	Dosage form	Indication	Dossier availability
OTHER THERAPEUTIC AREAS			
ANTIEMETICS			
Nabilone*	Film-coated tablets 1 mg	Antiemetic	Q3 2020
Ondansetron	Film-coated tablets 4 and 8 mg Orodispersible tablets 4 and 8 mg	Nausea & Vomiting	√
ANTI-INFECTIVES			
Azithromycin	Film-coated tablets 500 mg and Powder for oral suspension 200 mg/5 ml	Macrolide antibacterial	√
Ciprofloxacin otic	Ear drops, solution 1 mg (unit dose)	Otitis	√
Fluconazol	Capsules, hard 50, 100, 150 and 200 mg Powder for oral suspension 200 mg/5ml & 50mg/ 5ml	Antifungal	√
CARDIOVASCULAR			
Clopidogrel	Film-coated tablets 75 mg	Atherothrombosis	√
Enalapril	Tablets 5 and 20 mg	Hypertension	√
Enalapril + HCTZ	Tablets 20/12.5 mg	Hypertension	√
Imidapril [S]	Tablets 5, 10 and 20 mg	Hypertension	√
Irbesartan	Film-coated tablets 75, 150 and 300 mg	Hypertension	√
Irbesartan + HCTZ	Film-coated tablets 150/12.5, 300/12.5 & 300/25 mg	Hypertension	√
Lisinopril	Tablets 5 and 20 mg	Hypertension	√
Lisinopril + HCTZ	Tablets 20/12.5 mg	Hypertension	√
Prasugrel (Base)	Film-coated tablets 5 and 10 mg	Prophylaxis and therapy of thrombosis	√
Rivaroxaban	Film-coated tablets 10, 15 and 20 mg	Thrombosis, stroke	√
Valsartan	Film-coated tablets 40, 80, 160 and 320 mg	Hypertension	√
Valsartan + HCTZ	Film-coated tablets 80/12.5, 160/12.5, 320/12.5, 160/25, and 320/25 mg	Hypertension	√
OPHTHALMIC PRODUCTS			
Artificial tears Carmellose	2 mg eye drops, solution (unit dose)	Dry Eye	√
Artificial tears Hypromellose	0.5 ml eye drops, solution (unit dose)		
PAIN			
Dexketoprofen	Film-coated tablets 12.5 and 25 mg	Analgesic	√
Ketorolac	Film-coated tablets 10 mg	Analgesic	√
Paracetamol / Tramadol	Effervescent tablets 325/37.5 mg	Analgesic	√
Rizatriptan	Orodispersible tablets 5 and 10 mg	Migraine	√
Zolmitriptan	Orodispersible tablets 2.5 and 5 mg	Migraine	√
RESPIRATORY			
Desloratadine	Film-coated tablets 5 mg	Allergy	√
Loratadine	Film-coated tablets 10 mg	Allergy	√
Montelukast	Chewable tablets 4 & 5 mg and film-coated tablets 10 mg	Asthma, allergy	√

* Differentiated product

Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorisation. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorisation. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.

Product	Dosage form	Indication	Dossier availability
OTHERS			
Calcium Dobesilate [S]	Hard capsules 500 mg	Non proliferative diabetic retinopathy	√
Otilonium Bromide	Film-coated tablets 40 mg	Irritable bowel syndrome	√
Solifenacin	Film-coated tablets 5 and 10 mg	Overactive bladder, urinary incontinence	√

Product	Active Ingredients	Dosage form	Description	Launch date
CNS NUTRACEUTICALS				
Vivimind®	Homotaurine	Box of 40 tablets	Intended to protect memory and cognitive functions in MCI patients	Nov 2010
Viviflux®	Homotaurine + DHA + Folic Acid	Box of 20 capsules	Indicated for stroke primary and secondary prevention and for cerebrovascular disorders	Sep 2011
Vivifast®	Citicoline Cognizin® + Homotaurine + Vitamin E	Box of 20 tablets	Useful in the management of several types of cognitive disorders	Nov 2015
Seripnol®	L-Theanine + Magnolia + Ziziphus + Melatonin	Box of 28 sachets	Useful to promote relaxation and sleep	Mar 2012
Seripnol® drops	L-Theanine + Melatonin + Magnolia + Ziziphus	Oral drops. Bottle of 30 ml	Useful to promote relaxation and sleep	Apr 2014
Quetidia®	L-Theanine + Passiflora + Skullcap + Magnesium	Box of 30 tablets	Useful for the management of anxiety disorders	Sep 2014
Quetidia® oral solution	L-Theanine + Passiflora + Skullcap + Magnesium	Oral solution. Bottle of 150 ml	Useful for the management of anxiety disorders	Sep 2017
Triadenor®	N-Acetyl-Cystein + S-Adenosyl-LMethionine + Folic Acid	Box of 16 tablets	Useful for the management of depressive disorders	Nov 2014
Partena®	Magnesium + Parthenium + Andrographis Paniculata + Coenzyme Q10 + Vitamin B2	Box of 28 tablets	Rational combination for the prophylaxis of migraine, the nociceptive modulation and the reduction of tension states	Jan 2014
Noxiall®	PEA + Commiphora Myrrha + Rosmarinus Officinalis + Piper Nigrum (of which Beta Caryophyllene)	Box of 20 tablets	Useful to contrast chronic and neuropathic pain	Jan 2017
UMP+Folic Acid+B12	Uridine Monophosphate + Folic Acid + Vitamin B12	Box of 20 and 40 film-coated tablets	Useful for the treatment of spinal syndromes, neuralgias and polyneuropathies	Jul 2018

* Differentiated product

Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorisation. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorisation. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.